#oncolytics

[ahmedalshammari]

العلاج الفايروسي وتثبيط ايض الكلوكوز كعلاج للاورام Glycolysis inhibition...

تهدف الورشة الى التعريف بماهية العلاج الفايروسي وكيفية استهداف مسار ايض الكلوكوز في الخلايا السرطانية كهدف علاجي مهم حيث تعتمد الخلايا السرطانيية على مسار الايض الهوائي للكلوكوز فقط لانتاج الطاقه وبالتالي فان استهداف هذا المسار وتثبيطه سيكون هدفا مهما لتجويع الخلايا السرطانية وحماية الخلايا الطبيعيه التي تمتلك مسار اخر يمكنها من انتاج الطاقه. اوضحت التجارب البحثية ان تثبيط مسار ايض الكلوكوز باستخدام مثبطات متخصصه وتعريض الخلايا السرطانية في نفس الوقت للعلاج الفايروسي اضهرت فعلا مضادا للاورام بشكل اكبر واقوى من العلاج المنفرد. Most cancer cells exhibit increased glycolysis and use this metabolic pathway cell growth and proliferation. Targeting cancer cells’ metabolism is a promising strategy in inhibiting cancer cell progression. We used specific hexokinase inhibitors, to inhibit glycolysis to enhance the Newcastle disease virus anti-tumor effect. this presentation to explain this novel anti-tumor new strategy. The slides in English but the talk is in Arabic.

[ahmedalshammari]

Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy Ahmed Majeed Al-Shammari,1 Huda Rameez,2 Maha F Al-Taee2 1Department of Experimental Therapy, Iraqi Center for Cancer and Medical Genetic Research, Mustansiriyah University, 2Department of Biotechnology, College of Science, Baghdad University, Baghdad, IraqAbstract: Hematological malignancies are important diseases that need more powerful therapeutics. Even with current targeting therapies, such as rituximab and other chemotherapeutic agents, there is a need to develop new treatment strategies. Combination therapy seems the best option to target the tumor cells by different mechanisms. Virotherapy is a very promising treatment modality, as it is selective, safe, and causes cancer destruction. The Iraqi strain of Newcastle disease virus (NDV) has proved to be effective both in vitro and in vivo. In the current work, we tested its ability on anti-hematological tumors and enhanced current treatments with combination therapy, and studied this combination using Chou–Talalay analysis. p53 concentration was measured to evaluate the mechanism of this proposed synergism. The results showed that NDV was synergistic with doxorubicin in low doses on plasmacytoma cells, with no involvement of p53 pathways, but involved p53 when the combination was used on non-Hodgkin lymphoma cells. NDV in combination with rituximab showed enhanced cytotoxicity that was p53-independent. In conclusion, this work proposes a novel combination modality for treatment of some hematological malignancies.Keywords: oncolytic viruses, virotherapy, combination therapy

My students and I work hard in my lab to develop anti-cancer agents that is smart and target only the transformed cancer cells, and work in synergism with chemotherapeutics, in this work we targeted h...

[dududara]

Cancer: Hope for humanity as Canada develops new therapy

Cancer: Hope for humanity as Canada develops new therapy

Diagram showing prostate cancer pressing on the urethra…hope for patients rises

By Olajide Fashikun with Agency Report

Dr Robert Korneluk, a Canadian doctor is combining two trial cancer therapies in to a new treatment that he says will deliver a “one-two punch” to the illness.

“It’s not a matter of if it’ll go into the clinic, it’s a matter of when and that to me is the basis of my…

View On WordPress